Long Read Sequencing Market Size, Share & Trends by Offerings (Consumables, Instruments, Services), Workflow (Sample Prep, Sequencing, Data Analysis), Technology (Nanopore, SMRT), Application (WGS, WES, Epigenetics), Usage (Clinical, Research) - Global Forecast to 2029
The long-read sequencing market is expected to reach USD 3,129 million in 2029 from USD 758 million in 2024, at a CAGR of 32.8% during the forecast period. Growth in the long-read sequencing marke... もっと見る
日本語のページは自動翻訳を利用し作成しています。
SummaryThe long-read sequencing market is expected to reach USD 3,129 million in 2029 from USD 758 million in 2024, at a CAGR of 32.8% during the forecast period.Growth in the long-read sequencing market is mainly driven by factors like increasing collaborations between academic institutions and industry players, decreased cost of sequencing, and continuous technological advancements in long-read sequencing. Moreover, the application of LRS like de novo genome assembly, structural variant detection, transcriptomics, and epigenetics is supporting the market growth. However, the initial cost concern to set up the equipment is impacting the growth of the long-read sequencing market. “The consumables segment accounted for the largest share by offerings segment in the long-read sequencing market in 2023” The long-read sequencing market is segmented into consumables, instruments, and services in 2023. The consumables is the segment with the largest share in offerings. The large share of consumables is due to their role in sample preparation, sequencing, and data analysis part of long-read sequencing. As the demand for sequencing increases, it supports the demand for the consumables segment, driving its growth in the market. Still, the instrument segment held the second-largest market share. “The academic & research institutes segment accounted for the largest share by end-user segment in the long-read sequencing market in 2023” The long-read sequencing market is segmented into academic & research institutes, pharmaceutical & biotechnologies companies, hospitals, clinics & diagnostics laboratories, and other end users. The academic & research institutes are the segment with the largest share in the end-user segment in 2023. The large share of academic & research institutes is due to the increased demand for whole genome sequencing products, and increased genomics research. However, the pharmaceutical & biotechnological companies accounted for the second largest share in the segment. “The Asia Pacific region is growing at the highest CAGR in the long-read sequencing market from 2024 to 2029.” The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the large scale of population genomics projects, and the demand for precision medicines is supporting the growth. Further, the rising prevalence of chronic diseases is attributed to the aging population of countries such as Japan, and China. These is supporting the adoption of sequencing technologies in healthcare prognosis and treatment driving the market growth. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side- 70% and Demand Side 30% • By Designation: Managers - 45% CXOs and Director-level - 30%, and Executives - 25%, • By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%. List of Companies Profiled in the Report: • Oxford Nanopore Technologies plc. (UK) • PacBio (US) • Illumina, Inc. (US) • Agilent Technologies, Inc. (US) • Thermo Fisher Scientific Inc. (US) • 10X Genomics, Inc. (US) • QIAGEN (Germany) • BGI Group (China) • Takara Bio Inc. (Japan) • Azenta US, Inc. (US) • Revvity, Inc. (US) • Danaher Corporation (US) • Novogene Co., Ltd. (China) • New England Biolabs (US) • BaseClear BV (Netherlands) • Element Biosciences (US) • Grandomics (China) • CD Genomics (US) • Sage Sciences, Inc. (US) • EdenRoc Sciences (US) Research Coverage: This research report categorizes the long-read sequencing market by offerings (instruments, consumables, and services), technology (single-molecule real-time sequencing, nanopore sequencing, and synthetic long-read sequencing), workflow (sample preparation, sequencing, and data analysis), application (whole genome sequencing, metagenomics, epigenetics, targeted sequencing, whole exome sequencing, and other applications), usage (research and clinical), end user (academic & research institutes, pharmaceutical & biotechnology companies, hospitals, clinics & diagnostic Labs, and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the long-read sequencing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as collaborations, expansions, agreements, and recent developments associated with the long-read sequencing market. Competitive analysis of top players and upcoming startups in the long-read sequencing market ecosystem is covered in this report. Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall long-read sequencing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights on the following pointers: Analysis of key drivers (Technological advancements in genome sequencing, Increased prevalence of complex and rare genetic disorders, and growing demand for high-quality throughput screening), restraints (High investments to develop long read sequencing technologies, Technical Limitations of existing technology), opportunities (Rising demand for long-read sequencing in clinical genomics, and expanding applications of long-read sequencing), and challenges (challenges associated with data preservation, analysis, and validation) influencing the growth of the market. • Product Development/Innovation: Detailed insights on newly launched services of the long-read sequencing market • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions. • Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the long-read sequencing market • Competitive Assessment: Oxford Nanopore Technologies plc. (UK), PacBio (US), Illumina, Inc. (US), Agilent Technologies, Inc. (US), Thermo Fisher Scientific Inc. (US), 10X Genomics, Inc. (US), QIAGEN (Germany), BGI Group (China), Takara Bio Inc. (Japan), Azenta US, Inc. (US), Revvity, Inc. (US), Danaher Corporation (US), Novogene Co., Ltd. (China), New England Biolabs (US), BaseClear BV (Netherlands), Element Biosciences (US), Grandomics (China), CD Genomics (US), Sage Sciences, Inc. (US), and EdenRoc Sciences (US) among others in the market. Table of Contents1 INTRODUCTION 311.1 STUDY OBJECTIVES 31 1.2 MARKET DEFINITION 31 1.2.1 INCLUSIONS & EXCLUSIONS 32 1.3 MARKET SCOPE 33 1.3.1 MARKETS COVERED 33 1.3.2 YEARS CONSIDERED 34 1.3.3 CURRENCY CONSIDERED 34 1.4 STAKEHOLDERS 34 2 RESEARCH METHODOLOGY 35 2.1 RESEARCH DATA 35 2.1.1 SECONDARY DATA 35 2.1.2 PRIMARY DATA 36 2.2 MARKET ESTIMATION METHODOLOGY 38 2.2.1 MARKET SIZE ESTIMATION 38 2.2.2 TOP-DOWN APPROACH 41 2.3 MARKET GROWTH RATE PROJECTIONS 42 2.4 DATA TRIANGULATION 44 2.5 RESEARCH ASSUMPTIONS 44 2.6 RESEARCH LIMITATIONS 45 2.7 RISK ANALYSIS 45 3 EXECUTIVE SUMMARY 46 4 PREMIUM INSIGHTS 51 4.1 LONG-READ SEQUENCING MARKET OVERVIEW 51 4.2 ASIA PACIFIC: LONG-READ SEQUENCING MARKET, BY OFFERING 52 4.3 LONG-READ SEQUENCING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53 4.4 LONG-READ SEQUENCING MARKET SHARE, BY END USER, 2023 53 5 MARKET OVERVIEW 54 5.1 INTRODUCTION 54 5.2 MARKET DYNAMICS 54 5.2.1 DRIVERS 55 5.2.1.1 Emerging technological advancements 55 5.2.1.2 Increasing prevalence of complex and rare genetic disorders 56 5.2.1.3 Growing demand for high-throughput sequencing 56 5.2.1.4 Expanding applications of long-read sequencing 57 5.2.2 RESTRAINTS 57 5.2.2.1 High investment cost 57 5.2.2.2 Technical limitations of existing technologies 58 5.2.3 OPPORTUNITIES 58 5.2.3.1 Rising adoption in clinical genomics 58 5.2.4 CHALLENGES 58 5.2.4.1 Data preservation, analysis, and validation issues 58 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 59 5.4 REGULATORY LANDSCAPE 59 5.4.1 REGULATORY SCENARIO 59 5.4.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 60 5.5 VALUE CHAIN ANALYSIS 62 5.6 TECHNOLOGICAL ANALYSIS 64 5.6.1 KEY TECHNOLOGIES 64 5.6.1.1 Single-molecule real-time sequencing 64 5.6.1.2 Nanopore sequencing 65 5.6.1.3 Synthetic long-read sequencing 65 5.6.2 COMPLEMENTARY TECHNOLOGIES 66 5.6.2.1 Next-generation sequencing combined with artificial intelligence 66 5.6.2.2 Single-cell sequencing 66 5.6.2.3 Polymerase chain reaction 66 5.6.3 ADJACENT TECHNOLOGIES 67 5.6.3.1 Sample preparation technologies 67 5.6.3.2 Data analysis 67 5.7 PRICING ANALYSIS 68 5.7.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY OFFERING 68 5.7.2 AVERAGE SELLING PRICE OF KEY PLAYERS, BY INSTRUMENT 68 5.7.3 AVERAGE SELLING PRICE OF KEY PLAYERS, BY CONSUMABLE 69 5.7.4 AVERAGE SELLING PRICE OF KEY PLAYERS, BY SERVICE 70 5.7.5 AVERAGE SELLING PRICE, BY REGION 71 5.8 PATENT ANALYSIS 72 5.9 SUPPLY CHAIN ANALYSIS 74 5.10 ECOSYSTEM ANALYSIS 75 5.11 KEY CONFERENCES & EVENTS, 2024–2025 77 5.12 PORTER’S FIVE FORCES ANALYSIS 78 5.12.1 PORTER’S FIVE FORCES ANALYSIS 78 5.12.2 INTENSITY OF COMPETITIVE RIVALRY 79 5.12.3 BARGAINING POWER OF SUPPLIERS 79 5.12.4 BARGAINING POWER OF BUYERS 79 5.12.5 THREAT OF SUBSTITUTES 79 5.12.6 THREAT OF NEW ENTRANTS 79 5.13 KEY STAKEHOLDERS & BUYING CRITERIA 80 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 80 5.13.2 KEY BUYING CRITERIA, BY END USER 80 5.14 INVESTMENT & FUNDING SCENARIO 82 5.15 CASE STUDY ANALYSIS 82 5.15.1 ENHANCED DETECTION OF AMYOTROPHIC LATERAL SCLEROSIS USING PACBIO SINGLE-MOLECULE, REAL-TIME SEQUENCING 82 5.15.2 IMPROVED DIAGNOSIS OF RARE DISEASES WITH LONG-READ WHOLE-GENOME SEQUENCING 83 5.16 IMPACT OF AI ON LONG-READ SEQUENCING MARKET 83 6 LONG-READ SEQUENCING MARKET, BY OFFERING 84 6.1 INTRODUCTION 85 6.2 CONSUMABLES 85 6.2.1 LARGE NUMBER OF PLAYERS OPERATING IN CONSUMABLES SPACE TO PROPEL DEMAND 85 6.3 INSTRUMENTS 88 6.3.1 ADVANCEMENTS IN LONG-READ SEQUENCING TECHNOLOGY TO BOOST MARKET GROWTH 88 6.4 SERVICES 91 6.4.1 RISING DEMAND FOR COMPREHENSIVE GENOMIC DATA IN CLINICAL GENOMICS TO FAVOR MARKET GROWTH 91 7 LONG-READ SEQUENCING MARKET, BY TECHNOLOGY 95 7.1 INTRODUCTION 96 7.2 NANOPORE SEQUENCING 96 7.2.1 DIRECT DETECTION OF DNA MODIFICATIONS DURING SEQUENCING TO DRIVE MARKET GROWTH 96 7.3 SINGLE-MOLECULE REAL-TIME SEQUENCING 100 7.3.1 HIGHLY ACCURATE LONG READS BY REPEATEDLY SEQUENCING CIRCULARIZED DNA TO DRIVE DEMAND 100 7.4 SYNTHETIC LONG-READ SEQUENCING 103 7.4.1 GROWING DEMAND FOR DETAILED AND COMPREHENSIVE GENOMIC DATA IN AREAS SUCH AS CLINICAL GENOMICS TO BOOST MARKET 103 8 LONG-READ SEQUENCING MARKET, BY WORKFLOW 106 8.1 INTRODUCTION 107 8.2 SEQUENCING 107 8.2.1 DIRECT DETECTION OF DNA MODIFICATIONS DURING SEQUENCING TO DRIVE MARKET GROWTH 107 8.3 SAMPLE PREPARATION 111 8.3.1 DEVELOPMENT OF ADVANCED LIBRARY PREPARATION SOLUTIONS TO BOOST MARKET 111 8.4 DATA ANALYSIS 114 8.4.1 DEVELOPMENT OF ADVANCED BIOINFORMATICS SOLUTIONS TO FAVOR MARKET GROWTH 114 9 LONG-READ SEQUENCING MARKET, BY APPLICATION 118 9.1 INTRODUCTION 119 9.2 WHOLE-GENOME SEQUENCING 119 9.2.1 INCREASING USE OF WGS IN RARE DISEASE RESEARCH TO DRIVE MARKET GROWTH 119 9.3 TARGETED SEQUENCING 123 9.3.1 RISING DEMAND FOR LONG-READ SEQUENCING IN DISEASE DIAGNOSTICS TO SUPPORT MARKET GROWTH 123 9.4 METAGENOMICS 126 9.4.1 GROWING DEMAND FOR HIGH-RESOLUTION AND ACCURATE METAGENOMIC DATA TO FUEL GROWTH 126 9.5 EPIGENETICS 129 9.5.1 ADVANTAGES OF LRS IN EPIGENETICS STUDIES TO BOOST DEMAND 129 9.6 WHOLE-EXOME SEQUENCING 132 9.6.1 GROWING DEMAND FOR PRECISION GENETICS TO FAVOR MARKET GROWTH 132 9.7 OTHER APPLICATIONS 135 10 LONG-READ SEQUENCING MARKET, BY USAGE 138 10.1 INTRODUCTION 139 10.2 RESEARCH USAGE 139 10.2.1 RISING RESEARCH COLLABORATIONS TO BOOST MARKET GROWTH 139 10.3 CLINICAL USAGE 142 10.3.1 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH 142 11 LONG-READ SEQUENCING MARKET, BY END USER 146 11.1 INTRODUCTION 147 11.2 ACADEMIC & RESEARCH INSTITUTES 147 11.2.1 ACADEMIC & RESEARCH INSTITUTES TO DOMINATE MARKET DURING FORECAST PERIOD 147 11.3 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 151 11.3.1 GROWING COLLABORATIONS BETWEEN LRS PLAYERS AND PHARMA-BIOTECH COMPANIES TO DRIVE GROWTH 151 11.4 HOSPITALS, CLINICS, AND DIAGNOSTIC LABS 154 11.4.1 RISING DEMAND FOR LONG-READ SEQUENCING IN HOSPITALS & CLINICS TO SUPPORT GROWTH 154 11.5 OTHER END USERS 157 12 LONG-READ SEQUENCING MARKET, BY REGION 160 12.1 INTRODUCTION 161 12.2 NORTH AMERICA 162 12.2.1 US 165 12.2.1.1 US to dominate North American long-read sequencing market during forecast period 165 12.2.2 CANADA 168 12.2.2.1 Increasing government initiatives in genomics research to aid market growth 168 12.3 EUROPE 171 12.3.1 GERMANY 173 12.3.1.1 Increased funding for genomic development and application to favor market growth 173 12.3.2 UK 176 12.3.2.1 Favorable NHS funding and increased number of patients with rare genetic diseases to spur market growth 176 12.3.3 FRANCE 179 12.3.3.1 Increasing government investment in genomics and proteomics research to augment market growth 179 12.3.4 ITALY 181 12.3.4.1 Developed research infrastructure and increased genomics investment to fuel market growth 181 12.3.5 SPAIN 184 12.3.5.1 Advancements in translational and personalized medicine sector to boost market growth 184 12.3.6 REST OF EUROPE 186 12.4 ASIA PACIFIC 189 12.4.1 CHINA 193 12.4.1.1 Favorable regulatory reforms and high patient population to aid market growth 193 12.4.2 JAPAN 196 12.4.2.1 Technological advancements and high government investments in biotechnology to augment market growth 196 12.4.3 INDIA 198 12.4.3.1 Favorable government initiatives for genomics research to drive market 198 12.4.4 SOUTH KOREA 201 12.4.4.1 Rising government investments in cancer treatments and precision medicine to support market growth 201 12.4.5 REST OF ASIA PACIFIC 203 12.5 LATIN AMERICA 206 12.5.1 BRAZIL 209 12.5.1.1 Increased public and private investments in sequencing technologies to spur market growth 209 12.5.2 MEXICO 211 12.5.2.1 Growing prevalence of chronic disease and increasing geriatric population to support market growth 211 12.5.3 ARGENTINA 213 12.5.3.1 Rising healthcare investments and increasing focus on public health services to propel market growth 213 12.5.4 REST OF LATIN AMERICA 216 12.6 MIDDLE EAST 218 12.6.1 GCC COUNTRIES 221 12.6.1.1 Saudi Arabia 223 12.6.1.1.1 High government healthcare expenditure and technological advancements to boost market growth 223 12.6.1.2 UAE 226 12.6.1.2.1 Increasing R&D investment and growing healthcare infrastructure to aid market growth 226 12.6.1.3 Rest of GCC Countries 229 12.6.2 REST OF MIDDLE EAST 231 12.7 AFRICA 234 12.7.1 GROWING FOCUS ON PRECISION MEDICINE TO PROPEL MARKET GROWTH 234 13 COMPETITIVE LANDSCAPE 237 13.1 INTRODUCTION 237 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN 237 13.3 REVENUE ANALYSIS 239 13.4 MARKET SHARE ANALYSIS 240 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 243 13.5.1 STARS 243 13.5.2 EMERGING LEADERS 243 13.5.3 PERVASIVE PLAYERS 243 13.5.4 PARTICIPANTS 243 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 245 13.5.5.1 Company footprint 245 13.5.5.2 Region footprint 245 13.5.5.3 Offering footprint 246 13.5.5.4 Application footprint 247 13.5.5.5 Technology footprint 247 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 248 13.6.1 PROGRESSIVE COMPANIES 248 13.6.2 RESPONSIVE COMPANIES 248 13.6.3 DYNAMIC COMPANIES 248 13.6.4 STARTING BLOCKS 248 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 249 13.7 COMPANY VALUATION & FINANCIAL METRICS 250 13.8 BRAND/SERVICE COMPARISON 252 13.8.1 OXFORD NANOPORE TECHNOLOGIES PLC 252 13.8.2 PACBIO 253 13.8.3 ILLUMINA, INC. 253 13.8.4 AGILENT TECHNOLOGIES, INC. 253 13.8.5 THERMO FISHER SCIENTIFIC INC. 253 13.9 COMPETITIVE SCENARIO 253 13.9.1 DEALS 253 13.9.2 EXPANSIONS 254 14 COMPANY PROFILES 255 14.1 KEY PLAYERS 255 14.1.1 OXFORD NANOPORE TECHNOLOGIES PLC 255 14.1.1.1 Business overview 255 14.1.1.2 Products & services offered 256 14.1.1.3 Recent developments 257 14.1.1.3.1 Deals 257 14.1.1.4 MnM view 258 14.1.1.4.1 Right to win 258 14.1.1.4.2 Strategic choices 258 14.1.1.4.3 Weaknesses and competitive threats 258 14.1.2 PACBIO 259 14.1.2.1 Business overview 259 14.1.2.2 Products & services offered 260 14.1.2.3 Recent developments 262 14.1.2.3.1 Product & service launches 262 14.1.2.3.2 Deals 262 14.1.2.3.3 Expansions 263 14.1.2.3.4 Other developments 263 14.1.2.4 MnM view 264 14.1.2.4.1 Right to win 264 14.1.2.4.2 Strategic choices 264 14.1.2.4.3 Weaknesses and competitive threats 264 14.1.3 ILLUMINA, INC. 265 14.1.3.1 Business overview 265 14.1.3.2 Products & services offered 266 14.1.3.3 Recent developments 267 14.1.3.3.1 Product launches 267 14.1.3.4 MnM view 268 14.1.3.4.1 Key strengths 268 14.1.3.4.2 Strategic choices 268 14.1.3.4.3 Weaknesses and competitive threats 268 14.1.4 AGILENT TECHNOLOGIES, INC. 269 14.1.4.1 Business overview 269 14.1.4.2 Products & services offered 270 14.1.5 THERMO FISHER SCIENTIFIC INC. 272 14.1.5.1 Business overview 272 14.1.5.2 Products & services offered 273 14.1.6 10X GENOMICS, INC. 275 14.1.6.1 Business overview 275 14.1.6.2 Products & services offered 276 14.1.6.3 Recent developments 277 14.1.6.3.1 Product launches 277 14.1.7 QIAGEN 278 14.1.7.1 Business overview 278 14.1.7.2 Products & services offered 279 14.1.7.3 Recent developments 280 14.1.7.3.1 Expansions 280 14.1.8 BGI GROUP 281 14.1.8.1 Business overview 281 14.1.8.2 Products & services offered 281 14.1.9 AZENTA US, INC. 282 14.1.9.1 Business overview 282 14.1.9.2 Products & services offered 283 14.1.9.3 Recent developments 284 14.1.9.3.1 Expansions 284 14.1.10 TAKARA BIO INC. 285 14.1.10.1 Business overview 285 14.1.10.2 Products & services offered 286 14.1.10.3 Recent developments 287 14.1.10.3.1 Deals 287 14.1.11 NOVOGENE CO., LTD. 288 14.1.11.1 Business overview 288 14.1.11.2 Products & services offered 288 14.1.11.3 Recent developments 289 14.1.11.3.1 Other developments 289 14.1.12 REVVITY INC. 290 14.1.12.1 Business overview 290 14.1.12.2 Products & services offered 291 14.1.13 DANAHER CORPORATION 292 14.1.13.1 Business overview 292 14.1.13.2 Products & services offered 293 14.1.14 NEW ENGLAND BIOLABS 294 14.1.14.1 Business overview 294 14.1.14.2 Products & services offered 294 14.1.15 BASE CLEAR BV 295 14.1.15.1 Business overview 295 14.1.15.2 Products & services offered 295 14.2 OTHER PLAYERS 296 14.2.1 ELEMENT BIOSCIENCES 296 14.2.2 GRANDOMICS 296 14.2.3 CD GENOMICS 297 14.2.4 SAGE SCIENCES, INC. 298 14.2.5 EDENROC SCIENCES 298 15 APPENDIX 299 15.1 DISCUSSION GUIDE 299 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 303 15.3 CUSTOMIZATION OPTIONS 305 15.4 RELATED REPORTS 305 15.5 AUTHOR DETAILS 306
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(データ解析)の最新刊レポートMarketsandMarkets 社の最新刊レポート
本レポートと同じKEY WORD(data analysis)の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/09/30 10:25 143.73 円 160.93 円 195.03 円 |